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Background/Aims: Obstruction of the main pancreatic 
duct (MPD) has been considered one of the major 
causes for pain in chronic pancreatitis (CP). In this 
study, we evaluated the efficacy of MPD stenting in 
painful CP, and tried to determine a guideline for 
stent removal. Methods: Sixteen patients with painful 
CP who underwent MPD stenting were included. 
Follow up ERCP was performed 3 months after stent-
ing in all patients. Stents were removed in patients 
who achieved pain relief, complete stone clearance, 
and decreased MPD diameter after 3 months. Re-
sults: Before stenting, ERCP showed MPD stricture in 
11 cases, MPD dilatation by stone in 1 case, con-
comitant stricture and stone in 4 cases. After stenting, 
complete pain relief was achieved in 13 patients 
(81.3%) and partial pain relief was achieved in 3 pa-
tient (18.7%). There was no patient whose pain was 
not relieved. Stents were removed in 7 patients who 
achieved pain relief, complete stone clearance, and 
decreased MPD diameter after 3 months. Decrease of 
MPD diameter was significantly greater in patient who 
could remove stent than those who could not (72.9% 
vs. 127.9% of initial MPD diameter, p=0.008). Con-
clusions: If partial or full pain relief is achieved after 
MPD stenting and follow up ERCP after 3 months 
shows decreased MPD diameter compared to the ini-
tial one, stent removal might be considered. (Gut and 
Liver 2007;1:63-67)
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INTRODUCTION
  The cause and course of pain, which is the main symp-
tom in chronic pancreatitis (CP), is diverse and the 
pathogenesis of pain has not been elucidated.1,2 Hence, a 
standardized therapy for pain is not available, and also it 
is difficult to evaluate the effectiveness of therapy. 
Therefore, treatment in painful CP has to be decided in-
dividually by cause, frequency, and severity of pain. 
Obstruction of the main pancreatic duct (MPD) by a 
stricture or stone is one of major causes for pain in CP, 
and endoscopic MPD stenting has been used widely as a 
less-invasive alternative to conventional surgery for the 
treatment of pain in CP.3,4 Although most studies re-
ported good short-term and mid-term outcome after 
stenting, the appropriate duration of stent placement, the 
optimal interval for exchanging stent and criteria for stent 
removal has not been clerarly defined.4-10 The aim of pres-
ent study were to evaluate the therapeutic effectiveness of 
MPD stenting and to analyze factors that might become 
clinical criteria for stent removal.
MATERIALS AND METHODS
1. Subjects
  Between January 1999 and July 2006, 19 patients treat-
ed with MPD stenting due to painful CP and those who 
underwent follow-up endoscopic retrograde cholangiopan-
creatography (ERCP) after 3 months were identified in 
the Severance Hospital. Three patients who underwent 
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Table 1. Demographic and Clinical Characteristics
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
n (%)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Sex (male/female)   11/5
Age (years)* 42.1±17.0
Etiology
  Alcohol     8
  Idiopathic     8
Initial ERCP finding
  Stricture 11 (68.8)
  Stone  1 (6.2)
  Stricture and stone  4 (25.0)
Location of lesions
  Head and neck  9 (56.3)
  Body  6 (37.5)
  Tail  1 (6.2)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
*Mean±SD.
Table 2. Short-Term Outcome after Main Pancreatic Duct 
Stenting
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
n (%)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Complete pain relief 13 (81.3)
Partial pain relief  3 (18.7)
No improvement  0 (0)
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
MPD stenting were excluded due to accompanying 
pseudocyst. To evaluate the efficacy of MPD stenting and 
analyze the factors related to the stent removal, we retro-
spectively assessed clinical variables such as age, gender, 
the cause of chronic pancreatitis, the finding of ERCP at 
stent insertion and removal, the location of lesion, the re-
sults of pancreatic duct stone retrieval as well as the 
presence or absence of pancreatic duct stone, the diame-
ter of the inserted stent, the change of the MPD diameter 
after stenting and duration of stent placement. The max-
imal MPD diameter was measured, with corrections made 
for magnification by multiplying the measured duct diam-
eter by the known endoscopic diameter divided by the en-
doscope diameter measured on the ERCP film. In addi-
tion, the ratio of MPD diameter after stenting for initial 
one was obtained.
2. Stenting technique
  ERCP (TJF-200, 240 Olympus Co., Tokyo, Japan) was 
performed under conscious sedation. After traversing the 
dominant pancreatic duct stricture or the pancreatic duct 
stone with a hydrophilic guidewire, a pancreatic sphinc-
terotomy was performed, and a 5-7 Fr plastic pancreatic 
stent or an 8.5-12 Fr plastic stent for biliary drainage was 
placed. For the cases with pancreatic duct stone, ex-
tracorporeal shock wave lithotripsy (ESWL) for stone 
fragmentation and endoscopic retrieval of pancreatic duct 
stone were attempted first, and then subsequently, stents 
were placed.
3. Evaluation of the effectiveness of therapy after 
stenting
  The effectiveness of therapy on pain after stenting was 
classified as follows; (i) complete pain relief: defined as 
withdrawal of analgesics, (ii) partial pain relief: defined as 
reduction of analgesics dose, and (iii) no improvement: 
defined as no change in analgesics dose.
4. Follow up ERCP and Criteria for stent removal
  Follow up ERCP was performed 3 months after stent-
ing in all patients. Stents were removed in patients who 
achieved pain relief, complete stone clearance, and de-
creased MPD diameter after 3 months.
5. Statistical analysis
  For the evaluation of the efficacy and the analysis of 
factors related to stent removal after MPD stenting, t-test 
was used for the comparison of continuous variables, and 
chi-square test was used for the comparison of categorical 
variables. For statistical analysis, the SPSS Window 13 
(SPSS, Inc, Chicago, IL, USA) was used and p value lower 
than 0.05 was considered to be statistically significant.
RESULTS
1. Demographic and clinical characteristics
  Among 16 patients, 11 (68.8%) and 5 patients (31.2%) 
male and female, and the mean age was 42.1±17.0 years. 
The cause of CP was alcoholic and idiopathic in 8 cases 
each. According to the Cambridge classification, initial 
ERCP showed feature of severe CP in all patients includ-
ing MPD stricture in 11 cases, MPD dilatation by stone 
in 1 case, concomitant stricture and stone in 4 cases. The 
location of stricture was head and neck in 9 cases, and 
body in 6 cases and tail in 1 case. Demographic and clin-
ical characteristics are presented in Table 1.
2. Main pancreatic duct stenting and complications
  In the presence of pancreatic stones, prior to main pan-
creatic duct stenting, the retrieval of pancreatic stones 
was attempted by ESWL and endoscopic retrieval. As the 
result, pancreatic duct stones were retrieved completely in 
2 out of 5 cases. The median diameter of inserted stent 
was 7 Fr (5-12 Fr), and the median duration of stent 
placement was 3.2 monthes. Complications of ERCP and 
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Table 3. Comparison between Stent Removed Group and Stent
Maintained Group
󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚󰠚
Stent removed Stent maintained p-valuegroup group
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Age (years)* 45.0±17.0 39.9±17.6 0.568
Sex 0.308
 Male 6 5
 Female 1 4
Etiology 1.000
 Alcohol 4 4
 Idiopathic 3 5
Lacation of lesions 0.126
 Head and neck 2 7
 Body and tail 5 2
Stricture 1.000
 Present 7 8
 None 0 1
Stone 0.308
 Present 1 4
 None 6 5
% of MPD† 72.9 127.9 0.008
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
*Mean±SD.
†Maximal MPD diameter is significantly greater in patient who
could remove the stent compare to those who can not (mean
72.9% vs. 127.9% of initial MPD diameter, p=0.008).
MPD, main pancreatic duct.
Fig. 1. ERCP finding after 
main pancreatic duct sten-
ting. (A) Pancreatogram be-
fore main pancreatic duct 
stenting (MPD) shows se-
vere chronic pancreatitis. 
(B) After 3 months, pan-
creatogram reveals a de-
creased maximal MPD di-
ameter (93.2% of initial 
maximal MPD diameter).
MPD stenting included bleeding in 2 cases which was as-
sociated with pancreatic sphincterotomy and treated with 
electric coagulation. No other major complication occur-
red.
3. The short-term therapeutic effectiveness of MPD 
stenting
  After stenting, complete pain relief was achieved in 13 
patients (81.3%) and partial pain relief in 3 patient 
(18.7%). There was no patient whose pain was not 
relieved. (Table 2). The cause of CP, the location of le-
sion, the presence or absence of main pancreatic duct 
stricture, the presence of pancreatic stone and with or 
without its retrieval, the increase or decrease of the diam-
eter of the MPD after stenting, and with or without stent 
removal showed no significant association with ther-
apeutic effectiveness after MPD stenting.
4. Follow up ERCP and stent removal
  In the follow up ERCP after 3 months, the maximal 
MPD diameter in the proximal area of stricture decreased 
in 9 cases (56.3%), increased in 6 cases (37.5%) and was 
unchanged in one case (6.2%). Among 9 patients who 
showed the decreased maximal MPD diameter after 3 
months, stents were removed in 7 patients who achieved 
pain relief, complete stone clearance, and decreased MPD 
diameter after 3 months (Fig. 1).
5. Comparison between stent removed group and 
stent maintained group
  Stents were removed in 7 patients (43.8%) and main-
tained in 9 patients (56.2%) after 3 months. Age, gender, 
the cause of chronic pancreatitis, the location of lesion, 
the presence or absence of MPD stricture, and the results 
of pancreatic duct stone retrieval as well as the presence 
or absence of pancreatic duct stone were not different be-
tween the two groups, but MPD diameter decrease was 
significantly greater in patient who could remove stent 
than those who could not (mean 72.9% vs. 127.9% of ini-
tial MPD diameter, p=0.008) (Table 3).
6. The results of long-term follow up
  The median follow up period from the day of stenting 
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to the last hostital visit of total 16 patients was 18.8 
months (range, 6.40-59.7 months). Pain was well con-
trolled in 6 patients of the stent removal group without 
additional stenting or surgery during median follow up 
period of 22.0 months (range 4.0-53.0 months). In 1 pa-
tient, pain recurred after 5.4 months, and eventually sur-
gery (partial pancreatectomy and splenectomy) was per-
formed. The mean number of the stent exchange was 2.8 
times in the stent maintained group, and in 1 case, the 
stent was eventually removed under the condition of pain 
control, and pain did not recur. Among 16 patients, 2 pa-
tients (12.5%) were diagnosed as pancreatic cancer after 
10.1 months and 57.5 months each.
DISCUSSION
  Pain is one of the main symptoms of CP, and 60 to 
70% of patients will develop pain during the course of 
the CP.1 Although pain is multifactorial, the increase of 
pressure in the pancreatic duct and the pancreatic paren-
chyma due to the main pancreatic duct obstruction and 
inflammatory infiltration of pancreatic nerves are consid-
ered important factors.2,11,12 In addition, complications of 
CP such as pseudocyst and bile duct obstruction have to 
be considered as the cause of pain. In chronic pancreatitis 
with such diverse etiologies of pain, it is very difficult to 
determine the leading cause of pain in each patient and 
to select the optimal therapy as well as to evaluate ther-
apeutic effectiveness objectively.
  Endoscopic MPD stenting has been introduced for the 
control of pain in CP in the late 1980s as a less-invasive 
alternative to conventional surgery.3,13 The aim of MPD 
stenting is to relieve pain by ductal decompression and 
facilitate the secretion of pancreatic juice.14 For these rea-
sons, MPD stenting seems to be useful for patient with 
one dominant stricture in the pancreatic head and up-
stream ductal dilatation.15,16 In previous studies, it has 
been reported that immediate pain relief was show in 
74-94% after MPD stenting in CP with main pancreatic 
duct obstruction.4,17,18 Nevertheless, most studies reported 
only short-term and mid-term therapeutic effectiveness af-
ter MPD stenting, and the long term therapeutic effective-
ness of MPD stenting was doubtful. According to a large 
multicenter retrospective study presented recently in 
Europe, pain relief was maintained continuously in 
long-term follow up after MPD stenting.5,19 In our study, 
complete or partial pain relief could be achieved in all 16 
patients with MPD stenting, and a reason for such high 
effectiveness might be that all subjects had the findings 
of the distal obstruction and proximal dilatation of the 
MPD due to pancreatic duct structure and pancreatic 
stones prior to stenting, which suggested that the major 
cause of pain was the elevation of the pressure in the 
pancreatic duct in these patients.
  Regarding the change of the MPD diameter after stent-
ing, Binmoeller et al have reported that the MPD diame-
ter was decreased a mean of 1.6 mm after stenting in 51 
out of 58 patients (88%).4 On the other hands, Morgan et 
al. have reported that the MPD diameter was increased a 
mean of 2.7 mm after stenting in 70% patients. 
Particularly, in the 77% of 26 patients who showed the 
improvement of pain after stenting, the MPD diameter 
was increased, and the MPD diameter was decreased in 
23%.  Thus, they concluded that the change of the MPD 
diameter after stenting was not a good indicator of pain 
relief.20 In our study, like later study, the increase or de-
crease of the diameter of MPD after stenting was not as-
sociated with the therapeutic effectiveness on pain. 
Therefore, our data suggested increased intraductal pres-
sure might be a cause for a pain, but ductal diameter was 
not associated with pain relief. More studies are needed 
to understand this contradicting result.
  The appropriate duration of stent placement, the opti-
mal interval for exchanging stent and the time of stent 
removal has not been clearly defined. The stent was ex-
changed in patients with recurrent pain or every 2-4 
months as scheduled.4-9 In addition, pain relief and dis-
appearance of the proximal MPD dilatation have been 
suggested to be clinical criteria for stent removal.5,10 In 
our study, stents were removed in patients who achieved 
pain relief, complete stone clearance, and decreased max-
imal MPD diameter after 3 months, but stents were ex-
changed, even if pain were improved, if pancreatic duct 
stones could not be retrieved or the maximal MPD diam-
eter were increased or not changed. When we analyzed 
the clinical variables retrospectively, the maximal MPD 
diameter was decreased a mean 3.4 mm in patient who 
could remove stent. Also, MPD diameter decrease was 
significantly greater in patient who could remove stent 
than those who could not (mean 72.9% vs. 127.9% of ini-
tial MPD diameter, p=0.008). Therefore, although MPD 
diameter decrease was not a good indicator of therapeutic 
effectiveness, it might be considered as a factor related to 
stent removal after MPD stenting. To consider the stent 
removal or exchange by performing the follow up ERCP 
after 3 months was in agreement with the results of pre-
vious studies that the continuous placement of the stent 
was not associated with the pain control and severe com-
plication like necrotizing pancreatitis or pancreatic ab-
scess could be prevented by the scheduled stent ex-
change.5,6 
  This study is limited by a relatively small population, 
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retrospective analysis and lack of control groups. It is also 
possible that the therapeutic effectiveness on pain after 
MPD stenting may be contributed to the retrieval of pan-
creatic duct stone, pancreatic sphincterotomy and the nat-
ural course of CP.
  In conclusion, MPD stenting is an effective therapy in 
CP for pain caused by the main pancreatic duct ob-
struction and if partial or full pain relief was achieved af-
ter MPD stenting and follow up ERCP showed decreased 
MPD diameter compared to the initial one after 3 
months, stent removal might be considered.
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